Current plan

Explorer

Upgrade

Payment details required

One or more limits reached

Daily profile views

0 / 3

Monthly profile views

0 / 15

Searches (last 30 days)

0 / 10

Add Entity

Startup Nation Finder

Current plan

Explorer

Pricing plans

Payment details required

Daily profile views

0 / 3

Monthly profile views

0 / 15

Searches (last 30 days)

0 / 10

Watchlist name*

Watchlist must have a valid name.

Description (optional)

0/300

Notifications Settings

Public content (accessible by all Finder users)

Add to List

Select notifications to recieve

Select all

Email Alerts

Receive notifications via email

Daily

Weekly

Monthly

Never

No Notifications are selected

Would you like to select any notifications?

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME#’s profile to become an administrator with editing privileges in
#COMPANY_NAME#’s page on Startup Nation Finder

The invitation to claim the profile was originally sent to

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME#’s profile to become an administrator with editing privileges in
#COMPANY_NAME#’s page on Startup Nation Finder

Please provide us the following information. Note that you need to have an email in this organization in order to claim the profile.

Name*

Work Email* (please provide your email in the organization)

Position*

Notes

8 Characters, Uppercase letter (A-Z),
Lowercase letter (a-z), Digit (0-9)

Passwords do not match

I agree to receive Informational Emails from Startup Nation Finder as defined in the Privacy Policy and Terms of Use

Already have an account?

Or continue with

Home > Multinationals > Novo Nordisk

Claimed by owner • Last Update Jun 24, 2025 • Suggest Edits • Claim Profile

Claimed by owner

Novo Nordisk

Pharmaceuticals • Denmark

PUBLIC on OMX on Oct, 1980

PUBLIC on NYSE on Sep, 1981

Novo Nordisk

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

MongoDB downgraded, Block upgraded: Wall Street's top analyst calls

#Acquired-by

Sector Update: Health Care Stocks Rise Late Afternoon

Sector Update: Health Care Stocks Higher Thursday Afternoon

Novo Nordisk Faces Class Action Over Victoza Generic Delay

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

Sector Update: Health Care Stocks Softer Late Afternoon

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $5.2 Billion Buyout

#Acquisition

Sector Update: Health Care Stocks Advance Late Afternoon

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

#Product Stage #Partners

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

#FDA approved/pending approval

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

#FDA approved/pending approval

Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk

Stocks to watch next week: BP, Diageo, Disney, Uber and WPP

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck

#Product Stage #Partners

Markets Stay Relatively Calm as Fragile Ceasefire Deal Follows Missile Strikes

Trending tickers: Boeing, Adobe, Exxon, Oracle and Novo Nordisk

Charter to combine with Cox, Take-Two reports mixed Q4 results: Morning Buzz

#Acquired-by

eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal

#Public Trading

Obesity Drugs Are a Potential $100 Billion Opportunity by 2030, Goldman Sachs Analysts Say

Weight-Loss Drug Frenzy Cements Novo Nordisk as Europe’s Most Valuable Company

Novo Nordisk Drugs Are Shaking Up Stock Markets Again

#Customers #Partners

Novo’s Blockbuster Ozempic Now Shows Kidney Promise, Hitting Rivals

#Customers #Partners

How weight loss drugs could have chain reaction in 'food ecosystem'

#Customers, Expand

Ozempic Maker Novo Drops After First Stock Split in a Decade

#Management Changes #Public Trading

Novo Nordisk A/S is a pharmaceutical company that specializes in diabetes care medications and devices. It produces insulin, GLP-1 analogs, obesity drugs, and biopharmaceuticals, as well as insulin pens, needles, and glucose monitoring devices.

Digital Innovation Hubs in major health-tech ecosystems worldwide to accelerate digital progress in defeating chronic diseases. The Hubs will connect with local start-ups and organizations, co-create solutions, and amplify Novo Nordisk's purpose. The network spans globally, with Hubs already launched in China, UK, Germany, Brazil, and Israel.

Founded

12/1923

In Israel Since

6/1989

Employees Worldwide

50,000+

Employees In Israel

51-200

Market Cap

$163.43B

Market Cap Update

7/2026

Country

Denmark

News

(26)

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

MongoDB downgraded, Block upgraded: Wall Street's top analyst calls

#Acquired-by

Sector Update: Health Care Stocks Rise Late Afternoon

Sector Update: Health Care Stocks Higher Thursday Afternoon

Novo Nordisk Faces Class Action Over Victoza Generic Delay

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

Sector Update: Health Care Stocks Softer Late Afternoon

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $5.2 Billion Buyout

#Acquisition

Sector Update: Health Care Stocks Advance Late Afternoon

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

#Product Stage #Partners

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

#FDA approved/pending approval

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

#FDA approved/pending approval

Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk

Stocks to watch next week: BP, Diageo, Disney, Uber and WPP

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck

#Product Stage #Partners

Markets Stay Relatively Calm as Fragile Ceasefire Deal Follows Missile Strikes

Trending tickers: Boeing, Adobe, Exxon, Oracle and Novo Nordisk

Charter to combine with Cox, Take-Two reports mixed Q4 results: Morning Buzz

#Acquired-by

eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal

#Public Trading

Obesity Drugs Are a Potential $100 Billion Opportunity by 2030, Goldman Sachs Analysts Say

Weight-Loss Drug Frenzy Cements Novo Nordisk as Europe’s Most Valuable Company

Novo Nordisk Drugs Are Shaking Up Stock Markets Again

#Customers #Partners

Novo’s Blockbuster Ozempic Now Shows Kidney Promise, Hitting Rivals

#Customers #Partners

How weight loss drugs could have chain reaction in 'food ecosystem'

#Customers, Expand

Ozempic Maker Novo Drops After First Stock Split in a Decade

#Management Changes #Public Trading

The Team

(3)

Galit Kopatz

Vice President & General Manager-Israel & Palestinian Territory

Samuel Scheer

Innovation Lead

Inbal Carmel Columbus

Open Innovation Analyst

Locations

Israel

Atir Yeda St 1, Kefar Sava, Israel

Offices Abroad

Novo Alle 1, 2880 Bagsværd, Denmark

Locations

Israel

Atir Yeda St 1, Kefar Sava, Israel

Offices Abroad

Novo Alle 1, 2880 Bagsværd, Denmark

Startup Nation Finder

Create Watchlist

Add to List